Case Study 1: Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers Steve Genovese is a 30-year-old attorney. He has had Type I Diabetes Mellitus since the age of 16. He denies any signs or symptoms of neuropathy. His hemoglobin A1C is <7%. His blood pressure is 126/76, pulse 66, and respiration 20. The chemistry panel reveals: – Na 137 mEq/L – K 3.7 mEq/L – CI 99 mEqu/L – BUN 10 mg/dL – Creatinine 0.6 mg/dL – Cholesterol 110 mg/dL – LDL 76 mg/dL – HDL 25 mg/dL – Triglycerides 70 mg/dL
- What is the clinical use and dosing of the angiotensin-converting enzyme inhibits based on diagnosis?
- What are the pharmacokinetics of ACE inhibitors? (include onset of action, peak of action, metabolism, half-life, and excretion)
